Nation-Wide Analysis of Glaucoma Medication Prescription in Fiscal Year of 2019 in Japan
Abstract
1. Introduction
2. Materials and Methods
3. Results
4. Discussion
5. Conclusions
Supplementary Materials
Funding
Institutional Review Board Statement
Informed Consent Statement
Data Availability Statement
Conflicts of Interest
References
- Newman-Casey, P.A.; Woodward, M.A.; Niziol, L.M.; Lee, P.P.; De Lott, L.B. Brand Medications and Medicare Part D: How Eye Care Providers’ Prescribing Patterns Influence Costs. Ophthalmology 2018, 125, 332–339. [Google Scholar] [CrossRef] [PubMed]
- Chen, E.M.; Kombo, N.; Teng, C.C.; Mruthyunjaya, P.; Nwanyanwu, K.; Parikh, R. Ophthalmic Medication Expenditures and Out-of-Pocket Spending: An Analysis of United States Prescriptions from 2007 through 2016. Ophthalmology 2020, 127, 1292–1302. [Google Scholar] [CrossRef] [PubMed]
- Connor, A.J.; Fraser, S.G. Glaucoma prescribing trends in England 2000 to 2012. Eye 2014, 28, 863–869. [Google Scholar] [CrossRef] [PubMed]
- Kolko, M.; Horwitz, A.; Thygesen, J.; Jeppesen, J.; Torp-Pedersen, C. The Prevalence and Incidence of Glaucoma in Denmark in a Fifteen Year Period: A Nationwide Study. PLoS ONE 2015, 10, e0132048. [Google Scholar] [CrossRef]
- Lin, J.C. The use of ocular hypotensive drugs for glaucoma treatment: Changing trend in Taiwan from 1997 to 2007. J. Glaucoma 2015, 24, 364–371. [Google Scholar] [CrossRef]
- Newman, A.R.; Andrew, N.H. Changes in Australian practice patterns for glaucoma management. Clin. Exp. Ophthalmol. 2019, 47, 571–580. [Google Scholar] [CrossRef]
- Macleod, S.M.; Clark, R.; Forrest, J.; Bain, M.; Bateman, N.; Azuara-Blanco, A. A review of glaucoma treatment in Scotland 1994–2004. Eye 2008, 22, 251–255. [Google Scholar] [CrossRef][Green Version]
- De Natale, R.; Le Pen, C.; Berdeaux, G. Efficiency of glaucoma drug regulation in 5 European countries: A 1995–2006 longitudinal prescription analysis. J. Glaucoma 2011, 20, 234–239. [Google Scholar] [CrossRef]
- Tanito, M.; Sugihara, K.; Hara, K.; Takai, Y. Different glaucoma types and glaucoma surgeries among different age groups. Graefe’s Arch. Clin. Exp. Ophthalmol. 2018, 256, 2013–2014. [Google Scholar] [CrossRef]
- Perera, N.; Pinnuck, B.C.; Jamieson, M.P.H.; Ling, D.; Williams, M.; Chen, O. Prescribing Trends of Topical Glaucoma Medications in Australia From 2001 to 2017. J. Glaucoma 2020, 29, 175–183. [Google Scholar] [CrossRef]
- Sugihara, K.; Fukuda, H.; Omura, T.; Tanito, M. Reasons for choice of glaucoma surgery in eyes not treated with anti-glaucoma medications. BMC Ophthalmol. 2022, 22, 145. [Google Scholar] [CrossRef] [PubMed]
- Yamamoto, T.; Iwase, A.; Araie, M.; Suzuki, Y.; Abe, H.; Shirato, S.; Kuwayama, Y.; Mishima, H.K.; Shimizu, H.; Tomita, G.; et al. The Tajimi Study report 2: Prevalence of primary angle closure and secondary glaucoma in a Japanese population. Ophthalmology 2005, 112, 1661–1669. [Google Scholar] [CrossRef] [PubMed]
- Blumberg, D.M.; Prager, A.J.; Liebmann, J.M.; Cioffi, G.A.; De Moraes, C.G. Cost-Related Medication Nonadherence and Cost-Saving Behaviors Among Patients With Glaucoma Before and After the Implementation of Medicare Part D. JAMA Ophthalmol. 2015, 133, 985–996. [Google Scholar] [CrossRef] [PubMed]
- Delavar, A.; Radha Saseendrakumar, B.; Weinreb, R.N.; Baxter, S.L. Racial and Ethnic Disparities in Cost-Related Barriers to Medication Adherence Among Patients With Glaucoma Enrolled in the National Institutes of Health All of Us Research Program. JAMA Ophthalmol. 2022, 140, 354–361. [Google Scholar] [CrossRef]
- Heng, J.S.; Wormald, R.; Khaw, P.T. Geographical variation in glaucoma prescribing trends in England 2008–2012: An observational ecological study. BMJ Open 2016, 6, e010429. [Google Scholar] [CrossRef]
- Kawai-Tsuboi, N.; Kawai, M.; Minami, Y.; Yoshida, A. A study of the association between patterns of eye drop prescription and medication usage in glaucoma subjects. J. Glaucoma 2015, 24, 202–206. [Google Scholar] [CrossRef]
- Naito, T.; Yoshikawa, K.; Namiguchi, K.; Mizoue, S.; Shiraishi, A.; Ichikawa, Y.; Fujiwara, M.; Miki, T.; Araki, R.; Umeda, Y.; et al. Comparison of success rates in eye drop instillation between sitting position and supine position. PLoS ONE 2018, 13, e0204363. [Google Scholar] [CrossRef]
- Yu, L.; Ding, K.; Luo, L.; Yu, Z. Prescribing trends of glaucoma drugs in six major cities of China from 2013 to 2017. PLoS ONE 2020, 15, e0227595. [Google Scholar] [CrossRef]
- Kashiwagi, K.; Furuya, T. Persistence with topical glaucoma therapy among newly diagnosed Japanese patients. Jpn. J. Ophthalmol. 2014, 58, 68–74. [Google Scholar] [CrossRef]
- Schmier, J.K.; Hulme-Lowe, C.K.; Covert, D.W. Adjunctive therapy patterns in glaucoma patients using prostaglandin analogs. Clin. Ophthalmol. 2014, 8, 1097–1104. [Google Scholar] [CrossRef]
- Dreer, L.E.; Girkin, C.; Mansberger, S.L. Determinants of medication adherence to topical glaucoma therapy. J. Glaucoma 2012, 21, 234–240. [Google Scholar] [CrossRef] [PubMed]
- Banerjee, I.; Bhadury, T.; Sengupta, T.; Roy, D. Drug Utilization Study in Ophthalmology Out-patient Department of a Medical College in India. Ann. Med. Health Sci. Res. 2014, 4, 667–670. [Google Scholar] [CrossRef] [PubMed]
- Tatham, A.J. The Use of Generic Medications for Glaucoma. J. Ophthalmol. 2020, 2020, 1651265. [Google Scholar] [CrossRef]
- Hogg, H.D.J.; Connor, A. 10-year trends in English primary care glaucoma prescribing. Eye 2020, 34, 192–196. [Google Scholar] [CrossRef] [PubMed]
- Aref, A.A. Generic drugs for the treatment of ocular conditions: Changing the treatment landscape. Expert Rev. Clin. Pharmacol. 2014, 7, 551–553. [Google Scholar] [CrossRef][Green Version]
- Chang, L.; Ong, E.L.; Bunce, C.; Brookes, J.; Papadopoulos, M.; Khaw, P.T. A review of the medical treatment of pediatric glaucomas at Moorfields Eye Hospital. J. Glaucoma 2013, 22, 601–607. [Google Scholar] [CrossRef]
- Aihara, M.; Lu, F.; Kawata, H.; Iwata, A.; Odani-Kawabata, N.; Shams, N.K. Omidenepag Isopropyl Versus Latanoprost in Primary Open-Angle Glaucoma and Ocular Hypertension: The Phase 3 AYAME Study. Am. J. Ophthalmol. 2020, 220, 53–63. [Google Scholar] [CrossRef]
- Matsuo, M.; Matsuoka, Y.; Tanito, M. Efficacy and Patient Tolerability of Omidenepag Isopropyl in the Treatment of Glaucoma and Ocular Hypertension. Clin. Ophthalmol. 2022, 16, 1261–1279. [Google Scholar] [CrossRef]
- Tanito, M.; Ishida, A.; Ichioka, S.; Takayanagi, Y.; Tsutsui, A.; Manabe, K.; Shirakami, T.; Sugihara, K.; Matsuo, M. Proposal of a simple grading system integrating cosmetic and tonometric aspects of prostaglandin-associated periorbitopathy. Medicine 2021, 100, e26874. [Google Scholar] [CrossRef]
- Nakakura, S.; Terao, E.; Fujisawa, Y.; Tabuchi, H.; Kiuchi, Y. Changes in Prostaglandin-associated Periorbital Syndrome After Switch from Conventional Prostaglandin F2α Treatment to Omidenepag Isopropyl in 11 Consecutive Patients. J. Glaucoma 2020, 29, 326–328. [Google Scholar] [CrossRef]
- Sakata, R.; Fujishiro, T.; Saito, H.; Nakamura, N.; Honjo, M.; Shirato, S.; Miyamoto, E.; Yamada, Y.; Aihara, M. Recovery of deepening of the upper eyelid sulcus after switching from prostaglandin FP receptor agonists to EP2 receptor agonist: A 3-month prospective analysis. Jpn. J. Ophthalmol. 2021, 65, 591–597. [Google Scholar] [CrossRef] [PubMed]
Class | Total | Single | FDC | Brand | Generic |
---|---|---|---|---|---|
PGF2α | 10 | 10 | - | 5 | 5 |
β + CAI | 6 | - | 6 | 3 | 3 |
α2-agonist | 1 | 1 | - | 1 | - |
CAI | 4 | 4 | - | 2 | 2 |
PG + β | 4 | - | 4 | 4 | - |
ROCK | 1 | 1 | - | 1 | - |
β-blocker | 3 | 3 | - | 2 | 1 |
PGEP2 | 1 | 1 | - | 1 | - |
Other | 2 | 2 | - | 2 | - |
Total | 32 | 22 | 10 | 21 | 11 |
Class | Total | Man | Woman | Single | FDC | Brand | Generic |
---|---|---|---|---|---|---|---|
PGF2α | 35,310,214 | 15,327,512 | 19,982,703 | 35,310,214 | - | 26,975,993 | 8,334,221 |
β + CAI | 31,298,874 | 14,252,703 | 17,046,171 | - | 31,298,874 | 24,087,264 | 7,211,610 |
α2-agonist | 27,871,841 | 13,159,152 | 14,712,689 | 27,871,841 | - | 27,871,841 | - |
CAI | 18,712,262 | 8,344,612 | 10,367,650 | 18,712,262 | 13,887,168 | 4,825,094 | |
PG + β | 12,119,545 | 5,518,501 | 6,601,044 | - | 12,119,545 | 12,119,545 | - |
ROCK | 11,273,786 | 5,580,787 | 5,692,999 | 11,273,786 | - | 11,273,786 | - |
β-blocker | 6,947,340 | 2,557,882 | 4,389,458 | 6,947,340 | - | 5,052,487 | 1,894,853 |
PGEP2 | 1,500,846 | 529,063 | 971,783 | 1,500,846 | - | 1,500,846 | - |
Other | 5,748,294 | 2,060,808 | 3,687,486 | 5,748,294 | - | 5,748,294 | - |
Total | 150,783,002 | 67,331,020 | 83,451,983 | 107,364,583 | 43,418,419 | 128,517,224 | 22,265,778 |
Variables | F Value | p-Value |
---|---|---|
Model 1 | ||
Age class | 49.6 | <0.0001 |
Sex | 7.4 | 0.0066 |
Single or FDC | 0.2 | 0.67 |
Brand or Generic | 5.1 | 0.032 |
Model 2 | ||
Age class | 30.2 | <0.0001 |
Sex * Age class | 2.0 | 0.0071 |
Single or FDC * Age class | 0.6 | 0.91 |
Brand or Generic * Age class | 10.9 | <0.0001 |
Publisher’s Note: MDPI stays neutral with regard to jurisdictional claims in published maps and institutional affiliations. |
© 2022 by the author. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
Share and Cite
Tanito, M. Nation-Wide Analysis of Glaucoma Medication Prescription in Fiscal Year of 2019 in Japan. J. Pers. Med. 2022, 12, 956. https://doi.org/10.3390/jpm12060956
Tanito M. Nation-Wide Analysis of Glaucoma Medication Prescription in Fiscal Year of 2019 in Japan. Journal of Personalized Medicine. 2022; 12(6):956. https://doi.org/10.3390/jpm12060956
Chicago/Turabian StyleTanito, Masaki. 2022. "Nation-Wide Analysis of Glaucoma Medication Prescription in Fiscal Year of 2019 in Japan" Journal of Personalized Medicine 12, no. 6: 956. https://doi.org/10.3390/jpm12060956
APA StyleTanito, M. (2022). Nation-Wide Analysis of Glaucoma Medication Prescription in Fiscal Year of 2019 in Japan. Journal of Personalized Medicine, 12(6), 956. https://doi.org/10.3390/jpm12060956